Contribution: Industrial Research Assistance Program – Contributions to Firms
Semathera Inc.
$491,493.00
Preclinical development and tox studies for biologic treating diabetic macular edema.
FY 2021-22 · 2021-12-23
Summary
Development of analytical methods allowing to determine the tolerability, pharmacokinetics and pharmacodynamics of various treatments under development for retinopathy. The results will allow the selection of the molecule continuing their developments towards the next stages of the IND-enabling preclinical studies.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
Westmount|Westmount, Quebec, Canada
Recipient Type
For-profit organization
Business Number
748799525
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 2 | 2021-12-23 | 2021-22 | $350,000.00 |
| 3 | 2021-12-23 | 2021-22 | $491,493.00 |
| 4 | 2021-12-23 | 2021-22 | $491,493.00 |
As published
Additional Information
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 179 days.
Additional Information (French)
Cet accord a été modifié 1 fois La date de fin du présent accord a été changé de 179 jours.
Agreement End Date
2023-10-31
Agreement Number
985236
Agreement Start Date
2021-12-23
Agreement Title
Preclinical development and tox studies for biologic treating diabetic macular edema.
Agreement Title (French)
Développement préclinique et études toxicologiques pour un produit biologique traitant l'œdème maculaire diabétique
Agreement Type
Contribution
Agreement Value
$491,493.00
Amendment Date
2023-07-19
Amendment Number
4
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
Development of analytical methods allowing to determine the tolerability, pharmacokinetics and pharmacodynamics of various treatments under development for retinopathy. The results will allow the selection of the molecule continuing their developments towards the next stages of the IND-enabling preclinical studies.
Description (French)
Développement de méthodes analytiques permettant de déterminer la tolérance, la pharmacocinétique et la pharmacodynamique de différents traitements en cours de développement pour la rétinopathie. Les résultats permettront de sélectionner la molécule qui assurera la continuité du développement vers les prochaines étapes des études précliniques permettant l'obtention d'un nouveau médicament de recherche (NMR).
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Notre-Dame-de-Grâce--Westmount
Federal Riding (French)
Notre-Dame-de-Grâce--Westmount
Federal Riding Number
24053
NAICS Code
54171
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
748799525
Recipient City
Westmount|Westmount
Recipient Country
CA
Recipient Legal Name
Semathera Inc.
Recipient Postal Code
H3Z 2S6
Recipient Province or Territory
QC
Recipient Type
F
Reference Number
172-2021-2022-Q4-985236
